Logo

Kamada to Commercialize Three Biosimilar Products in Israel

Share this

Kamada to Commercialize Three Biosimilar Products in Israel

Shots:

  • Kamada signs an agreement with two undisclosed international pharmacies to commercialize three biosimilar product candidates in Israel. The two pharmaceutical companies will be responsible for the development- manufacturing- and supply of three products
  • Following the approval from EMA and IMOH- the three products are expected to be launched in Israel b/w 2022 and 2024
  • The collaboration will expand Kamada’s biosimilar portfolio in Israel which already includes six products previously licensed from Alvotech

 ­ Ref: GlobeNewswire | Image: Globes English

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions